These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 2865903)

  • 1. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
    Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Psychopharmacology (Berl); 1976 Dec; 51(1):1-7. PubMed ID: 827770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Problem of neuronal reception and the dopamine hypothesis of schizophrenia].
    Lideman RR; Zlobina GP; Mukhin AG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(5):762-9. PubMed ID: 6106337
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine in schizophrenia: a review and reconceptualization.
    Davis KL; Kahn RS; Ko G; Davidson M
    Am J Psychiatry; 1991 Nov; 148(11):1474-86. PubMed ID: 1681750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptics, dopamine, and schizophrenia.
    Pickar D
    Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The two-syndrome concept and neuroendocrinology of schizophrenia.
    Crow TJ; Ferrier IN; Johnstone EC
    Psychiatr Clin North Am; 1986 Mar; 9(1):99-113. PubMed ID: 2870481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment.
    Ben-Shachar D; Pinhassi B; Youdim MB
    Eur J Pharmacol; 1991 Sep; 202(2):177-83. PubMed ID: 1687031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroendocrinology and schizophrenia research].
    Müller-Spahn F
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
    [No Abstract]   [Full Text] [Related]  

  • 13. Postsynaptic supersensitivity in schizophrenia.
    Pandey GN; Garver DL; Tamminga C; Ericksen S; Ali SI; Davis JM
    Am J Psychiatry; 1977 May; 134(5):518-22. PubMed ID: 848578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Etiology of schizophrenia: neurochemical aspects].
    de las Cuevas Castresana C; González de Rivera JL
    Neurologia; 1994 Feb; 9(2):54-9. PubMed ID: 7515627
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopamine and schizophrenia.
    Crow TJ; Johnstone EC; Longden A; Owen F
    Adv Biochem Psychopharmacol; 1978; 19():301-9. PubMed ID: 29450
    [No Abstract]   [Full Text] [Related]  

  • 16. The dopamine hypothesis of schizophrenia revisited.
    van Kammen DP
    Psychoneuroendocrinology; 1979 Jan; 4(1):37-46. PubMed ID: 39306
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.
    Koshikawa H; Suzuki E; Kanba S; Nibuya M; Ishizuki T; Kohno H; Kinoshita N; Shintani F; Yagi G; Nakaki T
    Yakubutsu Seishin Kodo; 1991 Feb; 11(1):79-81. PubMed ID: 1679276
    [No Abstract]   [Full Text] [Related]  

  • 18. Dopamine receptors and schizophrenia.
    Reynolds GP
    Biochem Soc Trans; 1996 Feb; 24(1):202-5. PubMed ID: 8674664
    [No Abstract]   [Full Text] [Related]  

  • 19. Abnormal neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.
    Nair NP; Lal S; Cervantes P; Yassa R; Guyda H
    Neuropsychobiology; 1979; 5(3):136-42. PubMed ID: 431802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.